NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On October 5, 2016, citing patient safety concerns, Alnylam announced the Company’s decision to discontinue development of revusiran, an investigational RNA interference therapeutic being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy. The Data Monitoring Committee of the study informed the Company that the benefit-risk profile for revusiran no longer supported continued dosing, which led the Company to discontinue the study.
Following the news, Alnylam stock has fallen as much as $33.00, or 47.01%, to $37.24 during intraday trading on October 6, 2016. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.